Vögtle-Junkert U
Immun Infekt. 1975 Apr;3(2):54-64.
The increasing animal rabies infection in the Federal Republic of Germany and the growing risk for man - in 1974 two people died from rabies consequences although inoculated - shows the necessily to protect all bitten patients and those exposed to a risk of rabies by a well-timed prophylactic immunization. Unfortunately the HEMPT-vaccine used in this country up to the beginning of 1974 did not the requirements because of the low rate of circulating neutralizing antibodies and the numerous neurological complications associated with this vaccination. The now commonly used duck embryo rabies vaccine (DEV) also induces only low antibody titers, therefore the active immunization in uncertain. A new type of vaccine cultivated on human diploid cells (HDCS-vaccine) is currently being investigated upon but is due to produce quickly antirabies antibody still in incubation and should be put on the market if it has been sufficiently tested. The question of cost for pre-exposure vaccination for man to be carried by the state is discussed.
德意志联邦共和国动物狂犬病感染率不断上升,给人类带来的风险也与日俱增——1974年有两人虽接种了疫苗但仍死于狂犬病——这表明有必要通过及时的预防性免疫来保护所有被咬伤的患者以及那些有感染狂犬病风险的人。不幸的是,截至1974年初该国使用的HEMPT疫苗不符合要求,因为其循环中和抗体水平较低,且与这种疫苗接种相关的神经并发症众多。目前常用的鸭胚狂犬病疫苗(DEV)也只能诱导出较低的抗体滴度,因此主动免疫效果不确定。一种新型的人二倍体细胞培养疫苗(HDCS疫苗)目前正在进行研究,但由于仍在研发中,预计能快速产生抗狂犬病抗体,若经过充分测试,应可投放市场。文中还讨论了由国家承担人类暴露前疫苗接种费用的问题。